Search

Your search keyword '"Herbert, Deanna"' showing total 26 results
Start Over Author "Herbert, Deanna"
26 results on '"Herbert, Deanna"'

3. Liver enzyme CYP2D6 gene and tardive dyskinesia

Author

Lu, Justin Y, Tiwari, Arun K, Freeman, Natalie, Zai, Gwyneth C, de Luca, Vincenzo, Müller, Daniel J, Tampakeras, Maria, Herbert, Deanna, Emmerson, Heather, Cheema, Sheraz Y, King, Nicole, Voineskos, Aristotle N, Potkin, Steven G, Lieberman, Jeffrey A, Meltzer, Herbert Y, Remington, Gary, Kennedy, James L, and Zai, Clement C

Subjects
Pharmacology and Pharmaceutical Sciences, Biological Sciences, Biomedical and Clinical Sciences, Genetics, Mental health, Adult, Antipsychotic Agents, Cytochrome P-450 CYP2D6, Female, Humans, Liver, Male, Middle Aged, Schizophrenia, Tardive Dyskinesia, White People, metabolizer phenotype, pharmacogenetics, schizophrenia, tardive dyskinesia, CYP2D6, Medical and Health Sciences, Pharmacology & Pharmacy, Pharmacology and pharmaceutical sciences
Abstract

Background: Tardive dyskinesia (TD) is an iatrogenic involuntary movement disorder occurring after extended antipsychotic use with unclear pathogenesis. CYP2D6 is a liver enzyme involved in antipsychotic metabolism and a well-studied gene candidate for TD. Materials & methods: We tested predicted CYP2D6 metabolizer phenotype with TD occurrence and severity in our two samples of European chronic schizophrenia patients (total n = 198, of which 82 had TD). Results: TD occurrence were associated with extreme metabolizer phenotype, controlling for age and sex (p = 0.012). In other words, individuals with either increased and no CYP2D6 activity were at higher risk of having TD. Conclusion: Unlike most previous findings, TD occurrence may be associated with both extremes of CYP2D6 metabolic activity rather than solely for poor metabolizers.

Published
2020

4. Investigation of the HSPG2 Gene in Tardive Dyskinesia - New Data and Meta-Analysis.

Author

Zai, Clement, Lee, Frankie, Tiwari, Arun, Lu, Justin, de Luca, Vincenzo, Maes, Miriam, Herbert, Deanna, Shahmirian, Anashe, Cheema, Sheraz, Zai, Gwyneth, Atukuri, Anupama, Sherman, Michael, Shaikh, Sajid, Tampakeras, Maria, Freeman, Natalie, King, Nicole, Müller, Daniel, Greenbaum, Lior, Lerer, Bernard, Voineskos, Aristotle, Potkin, Steven, Lieberman, Jeffrey, Meltzer, Herbert, Remington, Gary, and Kennedy, James

Subjects
meta-analysis, perlecan/heparan sulfate proteoglycan 2 (HSPG2), pharmacogenetics, schizophrenia, tardive dyskinesia
Abstract

Tardive dyskinesia (TD) is a movement disorder that may occur after extended use of antipsychotic medications. The etiopathophysiology is unclear; however, genetic factors play an important role. The Perlecan (HSPG2) gene was found to be significantly associated with TD in Japanese schizophrenia patients, and this association was subsequently replicated by an independent research group. To add to the evidence for this gene in TD, we conducted a meta-analysis specific to the relationship of HSPG2 rs2445142 with TD occurrence, while also adding our unpublished genotype data. Overall, we found a significant association of the G allele with TD occurrence (p = 0.0001); however, much of the effect appeared to originate from the discovery dataset. Nonetheless, most study samples exhibit the same trend of association with TD for the G allele. Our findings encourage further genetic and molecular studies of HSPG2 in TD.

Published
2018

5. Analysis of schizophrenia‐associated genetic markers in the HLA region as risk factors for tardive dyskinesia.

Author

Wang, Ruoyu, Lu, Justin Y., Herbert, Deanna, Lieberman, Jeffrey A., Meltzer, Herbert Y., Tiwari, Arun K., Remington, Gary, Kennedy, James L., and Zai, Clement C.

Subjects
TARDIVE dyskinesia, GENETIC markers, PEOPLE with schizophrenia, GENOTYPES, PHARMACOGENOMICS
Abstract

Objectives: The pathology of Tardive Dyskinesia (TD) has yet to be fully understood, but there have been proposed hypotheses for the cause of this condition. Our team previously reported a possible association of TD with the Complement Component C4 gene in the HLA region. In this study, we explored the HLA region further by examining two previously identified schizophrenia‐associated HLA‐region single‐nucleotide polymorphisms (SNPs), namely rs13194504 and rs210133. Methods: The SNPs rs13194504 and rs210133 were tested for association with the occurrence and severity of TD in a sample of 172 schizophrenia patients who were recruited for four studies from three different clinical sites in Canada and USA. Results: The rs13194504 AA genotype was associated with decreased severity for TD as measured by Abnormal Involuntary Movement Scale (AIMS) scores (p = 0.047) but not for TD occurrence. SNP rs210133 was not significantly associated with either TD occurrence or AIMS scores. Conclusion: Our findings suggest that the rs13194504 AA genotype may play a role in TD severity, while SNP rs210133 may not have a major role in the risk or severity of TD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Studying Stigma

Author

Herbert, Deanna

Subjects
Disability rights, Disabled persons, Health, Psychology and mental health, Social sciences
Abstract

There's been a lot of progress made since the Americans with Disabilities Act (ADA) was passed 33 years ago. But a new research project is looking at what many believe [...]

Published
2023

9. W5. INVESTIGATING THE GENETIC LINK BETWEEN HEART RATE VARIABILITY (HRV) AND ANXIETY DISORDERS: POLYGENIC RISK SCORE OVERLAP AND ASSOCIATION OF HRV GENOME-WIDE POLYMORPHISMS WITH ANXIETY

Author

Tomasi, Julia, primary, Lisoway, Amanda J., additional, Zai, Clement C., additional, Zai, Gwyneth, additional, Richter, Margaret A., additional, Herbert, Deanna, additional, Mohiuddin, Ayeshah G., additional, Sanches, Marcos, additional, Tiwari, Arun K., additional, and Kennedy, James L., additional

Published
2023
Full Text
View/download PDF

12. User Experiences of Pharmacogenomic Testing and Opinions among Psychiatry Patients.

Author

Virelli, Catherine R., Ebrahimi, Mahbod, Mohiuddin, Ayeshah G., Tomasi, Julia, Lisoway, Amanda J., Herbert, Deanna, Marshe, Victoria S., Kidd, Sean A., Ferenbok, Joseph, and Kennedy, James L.

Subjects
PATIENTS' attitudes, USER experience, GENETIC profile, FOCUS groups, PSYCHIATRY
Abstract

Pharmacogenomic testing (PGx) is a tool used to guide physicians in selecting an optimal medication for clients based on their genetic profile. The objective of this qualitative study is to understand patients' experiences with PGx testing as well as their opinions regarding the clinical adoption of such tests in psychiatry. A focus group was conducted to assess the needs of clients who had experience using a PGx test. Participants were recruited from a large study on PGx testing that offered physicians an opportunity to use PGx reports to guide psychotropic prescriptions. The focus group discussions were recorded, transcribed, and coded using NVivo to identify core themes. A total of 11 people participated in the focus group. Our analysis revealed that many participants were in favour of implementing PGx testing in psychiatric practice, and all expressed important considerations for patient-centred optimization of PGx testing. The main themes captured were: education and awareness among clinicians, cost considerations, PGx results-sharing and accessibility, and prospective benefits. The results of this study suggest that patients are keen to see PGx testing in widespread clinical care, but they report important opportunities to improve knowledge mobilization of PGx testing. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Association Study of the Complement Component C4 Gene in Tardive Dyskinesia

Author

Zai, Clement C., primary, Tiwari, Arun K., additional, Zai, Gwyneth C., additional, Freeman, Natalie, additional, Pouget, Jennie G., additional, Greco, James, additional, Tampakeras, Maria, additional, Shaikh, Sajid A., additional, Herbert, Deanna, additional, Emmerson, Heather, additional, Cheema, Sheraz Y., additional, Braganza, Nicole, additional, Müller, Daniel J., additional, Voineskos, Aristotle N., additional, Remington, Gary, additional, and Kennedy, James L., additional

Published
2019
Full Text
View/download PDF

20. F103NEW GENETIC FINDINGS IN TARDIVE DYSKINESIA: FROM CYP2D6 TO C4

Author

Zai, Clement, primary, Tiwari, Arun, additional, Cheema, Sheraz, additional, de Luca, Vincenzo, additional, Mueller, Daniel, additional, Herbert, Deanna, additional, Shahmirian, Anashe, additional, Freeman, Natalie, additional, Braganza, Nicole, additional, Voineskos, Aristotle, additional, Potkin, Steven, additional, Lieberman, Jeffrey, additional, Meltzer, Herbert, additional, Remington, Gary, additional, and Kennedy, James L., additional

Published
2019
Full Text
View/download PDF

22. Investigation of the HSPG2 Gene in Tardive Dyskinesia – New Data and Meta-Analysis

Author

Zai, Clement C., primary, Lee, Frankie H., additional, Tiwari, Arun K., additional, Lu, Justin Y., additional, Luca, Vincenzo de, additional, Maes, Miriam S., additional, Herbert, Deanna, additional, Shahmirian, Anashe, additional, Cheema, Sheraz Y., additional, Zai, Gwyneth C., additional, Atukuri, Anupama, additional, Sherman, Michael, additional, Shaikh, Sajid A., additional, Tampakeras, Maria, additional, Freeman, Natalie, additional, King, Nicole, additional, Müller, Daniel J., additional, Greenbaum, Lior, additional, Lerer, Bernard, additional, Voineskos, Aristotle N., additional, Potkin, Steven G., additional, Lieberman, Jeffrey A., additional, Meltzer, Herbert Y., additional, Remington, Gary, additional, and Kennedy, James L., additional

Published
2018
Full Text
View/download PDF

23. Liver Enzyme CYP2D6Gene and Tardive Dyskinesia

Author

Lu, Justin Y, Tiwari, Arun K, Freeman, Natalie, Zai, Gwyneth C, Luca, Vincenzo de, Müller, Daniel J, Tampakeras, Maria, Herbert, Deanna, Emmerson, Heather, Cheema, Sheraz Y, King, Nicole, Voineskos, Aristotle N, Potkin, Steven G, Lieberman, Jeffrey A, Meltzer, Herbert Y, Remington, Gary, Kennedy, James L, and Zai, Clement C

Abstract

Background:Tardive dyskinesia (TD) is an iatrogenic involuntary movement disorder occurring after extended antipsychotic use with unclear pathogenesis. CYP2D6is a liver enzyme involved in antipsychotic metabolism and a well-studied gene candidate for TD. Materials & methods:We tested predicted CYP2D6 metabolizer phenotype with TD occurrence and severity in our two samples of European chronic schizophrenia patients (total n = 198, of which 82 had TD). Results:TD occurrence were associated with extreme metabolizer phenotype, controlling for age and sex (p = 0.012). In other words, individuals with either increased and no CYP2D6 activity were at higher risk of having TD. Conclusion:Unlike most previous findings, TD occurrence may be associated with both extremes of CYP2D6 metabolic activity rather than solely for poor metabolizers.

Published
2020
Full Text
View/download PDF

24. Genome-Wide Association Study of Sleep Disturbances in Depressive Disorders

Author

Melhuish Beaupre, Lindsay M., Gonçalves, Vanessa F., Zai, Clement C., Tiwari, Arun K., Harripaul, Ricardo S., Herbert, Deanna, Freeman, Natalie, Müller, Daniel J., and Kennedy, James L.

Abstract

Sleep disturbance affects about 75% of depressed individuals and is associated with poorer patient outcomes. The genetics in this field is an emerging area of research. Thus far, only core circadian genes have been examined in this context. We expanded on this by performing a genome-wide association study (GWAS) followed by a preplanned hypothesis-driven analysis with 27 genes associated with the biology of sleep. All participants were diagnosed by their referring physician, completed the Beck Depression Inventory (BDI), and the Udvalg for Kliniske Undersogelser Side Effect Rating Scale at baseline. Our phenotype consisted of replies to 3 questions from these questionnaires. From standard GWAS chip data, imputations were performed. Baseline total BDI scores (n= 364) differed significantly between those with and those without sleep problems. We were unable to find any significant GWAS hits although our top hit was for changes in sleep and an intergenic marker near SNX18(p= 1.06 × 10–6). None of the markers in our hypothesis-driven analysis remained significant after applying Bonferroni corrections. Our top finding among these genes was for rs13019460 of Neuronal PAS Domain Protein 2 with changes in sleep (p= 0.0009). Overall, both analyses were unable to detect any significant associations in our modest sample though we did find some interesting preliminary associations worth further exploration.

Published
2020
Full Text
View/download PDF

25. research update. Studying Stigma.

Author

HERBERT, DEANNA

Abstract

The article focuses on a research project addressing the enduring issue of stigma faced by people with disabilities, despite progress since the Americans with Disabilities Act (ADA) was enacted. Topics discussed include the research's aim to combat stigma through training and awareness among human resource professionals and law enforcement personnel, ultimately improving employment opportunities and quality of life for individuals with disabilities.

Published
2023

26. General and limited partnerships are simple, offer tax advantages.

Author

Horowitz, Lewis and Herbert, Deanna

Abstract

Focuses on general and limited partnerships. Co-owners' operation of a business venture for profit; Absence of liability of limited partner for contributions beyond his partnership contribution; Flow-through taxation.

Published
1995

Catalog

Books, media, physical & digital resources
See catalog results